<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39453440</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-2027</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>PharmacoEconomics</Title><ISOAbbreviation>Pharmacoeconomics</ISOAbbreviation></Journal><ArticleTitle>Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40273-024-01441-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Knowing the health opportunity costs of funding decisions is crucial to assess whether the health gains associated with new interventions are larger than the health losses imposed by the displacement of resources. Empirical estimates based on the effect of health spending on health outcomes have been proposed in several countries, including Spain, as a proxy to capture these opportunity costs. However, there is a need to regularly update existing health opportunity cost estimates and to explore the role of omitted variable bias in these estimations.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this paper is to provide an updated and refined estimate of the causal impact of health spending on health in Spain that can be translated into an estimate of the incremental cost per quality-adjusted life-year produced by the Spanish national health system.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We applied fixed-effect models using data for 17 Spanish regions from 2002 until 2022 to estimate the impact of public health spending on health outcomes and explored the extent of omitted variable bias. Changes in these estimates over time were assessed and alternative specifications were tested.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Based on fixed-effect models with control variables, the estimated spending elasticity was 0.061, which translated into an incremental cost per quality-adjusted life-year of approximately €34,000. The bias-corrected elasticity was 0.075, with a corresponding incremental cost per quality-adjusted life-year of €27,000. We found that the estimated impact of spending on health decreases when recent years of data are added, and that the extent of omitted variable bias appears to increase, particularly when adding the COVID-19 pandemic period.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study provides an updated estimation of the incremental cost per quality-adjusted life-year produced by the Spanish national health system. The estimates provided can be easily updatable as new data become accessible, and the methods applied might be transferable to other settings with similar available data.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vallejo-Torres</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5833-6066</Identifier><AffiliationInfo><Affiliation>Department of Quantitative Methods in Economics and Management, University of Las Palmas de Gran Canaria, Juan de Quesada, 30, 35001, Las Palmas de Gran Canaria, Canary Islands, Spain. Laura.vallejo@ulpgc.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RTI2018-096365-J-I00</GrantID><Agency>Ministerio de Ciencia e Innovación</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Pharmacoeconomics</MedlineTA><NlmUniqueID>9212404</NlmUniqueID><ISSNLinking>1170-7690</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39453440</ArticleId><ArticleId IdType="doi">10.1007/s40273-024-01441-4</ArticleId><ArticleId IdType="pii">10.1007/s40273-024-01441-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Culyer AJ. Cost, context, and decisions in health economics and health technology assessment. Int J Technol Assess Health Care. 2018;34:434–41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0266462318000612</ArticleId><ArticleId IdType="pubmed">30326982</ArticleId></ArticleIdList></Reference><Reference><Citation>Sculpher M, Claxton K, Pearson SD. Developing a value framework: the need to reflect the opportunity costs of funding decisions. Value Health. 2017;20:234–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2016.11.021</ArticleId><ArticleId IdType="pubmed">28237201</ArticleId></ArticleIdList></Reference><Reference><Citation>Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(1–503):v–vi.</Citation></Reference><Reference><Citation>Edney LC, Karnon J, Haji Ali Afzali H, Cheng TC, Karnon J. Estimating the reference incremental cost-effectiveness ratio for the Australian health system. Pharmacoeconomics. 2018;36:239–52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-017-0585-2</ArticleId><ArticleId IdType="pubmed">29273843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Glob Health. 2018;3: e000964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2018-000964</ArticleId><ArticleId IdType="pubmed">30483412</ArticleId><ArticleId IdType="pmc">6231096</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27:746–61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.3633</ArticleId><ArticleId IdType="pubmed">29282798</ArticleId></ArticleIdList></Reference><Reference><Citation>Siverskog J, Henriksson M. Estimating the marginal cost of a life year in Sweden’s public healthcare sector. Eur J Health Econ. 2019;20:751–62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10198-019-01039-0</ArticleId><ArticleId IdType="pubmed">30796552</ArticleId><ArticleId IdType="pmc">6602994</ArticleId></ArticleIdList></Reference><Reference><Citation>Siverskog J, Henriksson M. The health cost of reducing hospital bed capacity. Soc Sci Med. 2022;313: 115399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2022.115399</ArticleId><ArticleId IdType="pubmed">36206659</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadhouders N, Koolman X, van Dijk C, Jeurissen P, Adang E. The marginal benefits of healthcare spending in the Netherlands: estimating cost-effectiveness thresholds using a translog production function. Health Econ. 2019;28:1331–44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.3946</ArticleId><ArticleId IdType="pubmed">31469510</ArticleId><ArticleId IdType="pmc">6851736</ArticleId></ArticleIdList></Reference><Reference><Citation>van Baal P, Perry-Duxbury M, Bakx P, Versteegh M, van Doorslaer E, Brouwer W. A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Econ. 2019;28:87–100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.3831</ArticleId><ArticleId IdType="pubmed">30273967</ArticleId></ArticleIdList></Reference><Reference><Citation>Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Health Policy Plan. 2020;35:546–55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/heapol/czz152</ArticleId><ArticleId IdType="pubmed">32125375</ArticleId><ArticleId IdType="pmc">7225568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochalek J, Wang H, Gu Y, Lomas J, Cutler H, Jin C. Informing a cost-effectiveness threshold for health technology assessment in China: a marginal productivity approach. Pharmacoeconomics. 2020;38:1319–31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-020-00954-y</ArticleId><ArticleId IdType="pubmed">32856280</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S, Lomas J, Claxton K, Longo F. How effective is marginal healthcare expenditure? New evidence from England for 2003/04 to 2012/13. Appl Health Econ Health Policy. 2021;19(6):885–903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40258-021-00663-3</ArticleId><ArticleId IdType="pubmed">34286470</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanness DJ, Lomas J, Ahn H. A health opportunity cost threshold for cost-effectiveness analysis in the United States. Ann Intern Med. 2021;174:25–32.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-1392</ArticleId><ArticleId IdType="pubmed">33136426</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa O, Rodríguez-Lesmes P, Orozco L, Ávila D, Enríquez H, Romano G, et al. Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia. Health Policy Plan. 2022;37:359–68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/heapol/czab146</ArticleId><ArticleId IdType="pubmed">34875689</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallejo-Torres L, García-Lorenzo B, Edney LC, Stadhouders N, Edoka I, Castilla-Rodríguez I, et al. Are estimates of the health opportunity cost being used to draw conclusions in published cost-effectiveness analyses? A scoping review in four countries. Appl Health Econ Health Policy. 2022;20:337–49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40258-021-00707-8</ArticleId><ArticleId IdType="pubmed">34964092</ArticleId></ArticleIdList></Reference><Reference><Citation>Edney LC, Lomas J, Karnon J, Vallejo-Torres L, Stadhouders N, Siverskog J, et al. Empirical estimates of the marginal cost of health produced by a healthcare system: methodological considerations from country-level estimates. Pharmacoeconomics. 2022;40(1):31–43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-021-01087-6</ArticleId><ArticleId IdType="pubmed">34585359</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallejo-Torres L, Claxton K, Edney LC, Karnon J, Lomas J, Ochalek J, et al. Challenges of calculating cost-effectiveness thresholds. Lancet Glob Health. 2023;11: e1508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(23)00351-0</ArticleId><ArticleId IdType="pubmed">37734789</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallejo-Torres L. The broader opportunity costs in the broader cost-effectiveness analysis framework. Appl Health Econ Health Policy. 2023;21:373–84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40258-023-00801-z</ArticleId><ArticleId IdType="pubmed">37043159</ArticleId><ArticleId IdType="pmc">10119227</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Fuente A. El cálculo de las necesidades de gasto regionales: notas para la discusión. Fedea Policy Papers 2015/07. 2015. http://www.fedea.net/documentos/pubs/fpp/2015/10/FPP2015‐07.pdf . Accessed 12 Oct 2024.</Citation></Reference><Reference><Citation>Oster E. Unobservable selection and coefficient stability: theory and evidence. J Business Econ Stat. 2019;37:187–204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07350015.2016.1227711</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryan ML, Rice N, Roberts J, Sechel C. Mental health and employment: a bounding approach using panel data. Oxf Bull Econ Stat. 2022;84:1018–51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/obes.12489</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Statistics. Life tables. 2022. https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&amp;cid=1254736177004&amp;menu=ultiDatos&amp;idp=1254735573002 . Accessed 12 Oct 2024.</Citation></Reference><Reference><Citation>Ministry of Health. National Health Survey of Spain. 2003, 2006, 2011, 2017. https://www.sanidad.gob.es/estadEstudios/estadisticas/encuestaNacional/ . Accessed 12 Oct 2024.</Citation></Reference><Reference><Citation>Ministry of Health. European Survey of Health in Spain 2009, 2014, 2020. https://www.sanidad.gob.es/estadEstudios/estadisticas/EncuestaEuropea/ . Accessed 12 Oct 2024.</Citation></Reference><Reference><Citation>Gaminde I, Roset M. Quality adjusted life expectancy. Discussion papers/17th Plenary Meeting of the Euroqol Group. 2001.</Citation></Reference><Reference><Citation>Ministry of Health. Key indicators of national health system. 2022. https://inclasns.sanidad.gob.es/main.html?lang=EN . Accessed 12 Oct 2024.</Citation></Reference><Reference><Citation>National Institute of Statistics. Population figures. 2022. https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&amp;cid=1254736176951&amp;menu=ultiDatos&amp;idp=1254735572981 . Accessed 12 Oct 2024.</Citation></Reference><Reference><Citation>National Institute of Statistics. Spanish regional accounts. 2022. https://www.ine.es/dyngs/INEbase/en/operacion.htm?c=Estadistica_C&amp;cid=1254736167628&amp;menu=ultiDatos&amp;idp=1254735576581 . Accessed 12 Oct 2024.</Citation></Reference><Reference><Citation>National Institute of Statistics. Economically Active Population Survey. 2022. https://www.ine.es/dyngs/INEbase/en/operacion.htm?c=Estadistica_C&amp;cid=1254736176918&amp;menu=ultiDatos&amp;idp=1254735976595 . Accessed 12 Oct 2024.</Citation></Reference><Reference><Citation>National Institute of Statistics. Quarterly Labour Cost Survey. 2022. https://www.ine.es/dyngs/INEbase/en/operacion.htm?c=Estadistica_C&amp;cid=1254736045053&amp;menu=ultiDatos&amp;idp=1254735976596 . Accessed 12 Oct 2024.</Citation></Reference><Reference><Citation>Ministry of Transport. Statistics of the price of urban floor. 2022. https://apps.fomento.gob.es/BoletinOnline2/?nivel=2&amp;orden=36000000 . Accessed 12 Oct 2024.</Citation></Reference><Reference><Citation>National Institute of Statistics. Consumer Price Index (CPI). 2022. https://www.ine.es/dyngs/INEbase/en/operacion.htm?c=Estadistica_C&amp;cid=1254736176802&amp;menu=ultiDatos&amp;idp=1254735976607 . Accessed 12 Oct 2024.</Citation></Reference><Reference><Citation>Brekke KR, Dalen DM, Straume OR. The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets. J Health Econ. 2023;90: 102778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhealeco.2023.102778</ArticleId><ArticleId IdType="pubmed">37343309</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>